IMR Press / EJGO / Volume 25 / Issue 3 / pii/2004187

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer

Show Less
1 Department of Obstetrics and Gynecology, Uluda? University, Faculty of Medicine, Bursa (Turkey)
Eur. J. Gynaecol. Oncol. 2004, 25(3), 379–380;
Published: 10 June 2004

The efficacy of the combination treatment of cisplatin, adriamycin and etoposide were retrospectively evaluated in 26 recurrent or metastatic endometrial cancer patients. One hundred and twenty-three treatment courses were observed. Patients received 20 mg/m2 cisplatin and 80 mg/m2 etoposide by continuous IV infusion for three days and adriamycin 40 mg/m2 IV the second day. Treatment courses were repeated every four weeks. Megestrol acetate, 160 mg/day, was added in six patients who had positive prog­esterone receptors. Ten (38.5%) women had complete and three (11.5%) patients had partial response with an overa11 response rate of 50%. Median follow-up was 24 months. Surviving patients were alive for four months and six years. Toxicity was mainly hema­tological and gastrointestinal ulcerations and stomatitis were also observed.

Endometrial cancer
Back to top